MedKoo Cat#: 317313 | Name: Benztropine Mesylate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Benztropine is a synthetic compound derived from the combination of atropine and diphenhydramine that acts centrally to antagonize M1 muscarinic acetylcholine receptors. Benztropine has been used in the management of Parkinson’s disease symptoms to address involuntary tremor and dystonia. It can also increase the availability of dopamine by inhibiting uptake through the dopamine transporter.

Chemical Structure

Benztropine Mesylate
CAS#132-17-2 (mesylate)

Theoretical Analysis

MedKoo Cat#: 317313

Name: Benztropine Mesylate

CAS#: 132-17-2 (mesylate)

Chemical Formula: C22H27NO4S

Exact Mass: 0.0000

Molecular Weight: 401.52

Elemental Analysis: C, 65.81; H, 6.78; N, 3.49; O, 15.94; S, 7.99

Price and Availability

Size Price Availability Quantity
1g USD 250.00 2 Weeks
5g USD 500.00 2 Weeks
10g USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Benztropine Mesylate; Cogentin; Cogentin mesylate; MLS000737056; Benztropine methanesulfonate; NSC42199; ST50997629; Benzotropine mesylate
IUPAC/Chemical Name
(1R,3r,5S)-3-(benzhydryloxy)-8-methyl-8-azabicyclo[3.2.1]octane methanesulfonate
InChi Key
CPFJLLXFNPCTDW-BWSPSPBFSA-N
InChi Code
InChI=1S/C21H25NO.CH4O3S/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17;1-5(2,3)4/h2-11,18-21H,12-15H2,1H3;1H3,(H,2,3,4)/t18-,19+,20+;
SMILES Code
CN1[C@@H]2C[C@@H](OC(C3=CC=CC=C3)C4=CC=CC=C4)C[C@H]1CC2.OS(C)(=O)=O
Appearance
White to light yellow crystalline powder.
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 401.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bogunovic O, Viswanathan R. Thrombocytopenia possibly associated with olanzapine and subsequently with benztropine mesylate. Psychosomatics. 2000 May-Jun;41(3):277-8. PubMed PMID: 10849461. 2: Jackson CW, Cunningham K. Compatibility of haloperidol lactate with benztropine mesylate. Am J Hosp Pharm. 1994 Dec 1;51(23):2962-3. PubMed PMID: 7879808. 3: Voinov H, Elefante V, Mujica R. Sinus bradycardia related to the use of benztropine mesylate. Am J Psychiatry. 1992 May;149(5):711. PubMed PMID: 1575268. 4: Rosenberg JM, Sideman M, Kampa IS, McGuire H, Kampa L. Effects of benztropine mesylate on haloperidol-induced prolactin secretion and serum haloperidol levels in rats. J Pharm Sci. 1984 Dec;73(12):1833-5. PubMed PMID: 6527272. 5: Baker LA, Cheng LY, Amara IB. The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry. 1983 Dec;143:584-90. PubMed PMID: 6362765. 6: Thaler JS. Effects of benztropine mesylate (Cogentin) on accommodation in normal volunteers. Am J Optom Physiol Opt. 1982 Nov;59(11):918-9. PubMed PMID: 7180936. 7: Halbreich U, Sachar EJ, Nathan RS, Asnis GM, Halpern FS. The effect of benztropine mesylate on the prolactin response to haloperidol. Psychopharmacology (Berl). 1980;72(1):61-5. PubMed PMID: 6781007. 8: Rapp MS. Benztropine mesylate and social anxiety. Am J Psychiatry. 1979 Dec;136(12):1611. PubMed PMID: 507226. 9: Sovner R, Dimascio A. The effect of benztropine mesylate in the rabbit syndrome and tardive dyskinesia. Am J Psychiatry. 1977 Nov;134(11):1301-2. PubMed PMID: 910992. 10: Stenson RL, Donion PT, Meyer JE. Comparison of benztropine mesylate and amantadine HCl in neuroleptic-induced extrapyramidal symptoms. Compr Psychiatry. 1976 Nov-Dec;17(6):763-8. PubMed PMID: 791573. 11: el-Yousef MK, Manier DH. Letter: The effect of benztropine mesylate on plasma levels of butaperazine maleate. Am J Psychiatry. 1974 Apr;131(4):471-2. PubMed PMID: 4149998. 12: Kelly JT, Zimmermann RL, Abuzzahab FS, Schiele BC. A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism. Pharmacology. 1974;12(2):65-73. PubMed PMID: 4610599. 13: Stricklin MC. Collaborative study of a colorimetric determination of benztropine mesylate in tablets and injections. J Assoc Off Anal Chem. 1973 May;56(3):681-3. PubMed PMID: 4779907. 14: Mushet GR, Dreifuss FE. Paroxysmal dyskinesia. A case responsive to benztropine mesylate. Arch Dis Child. 1967 Dec;42(226):654-6. PubMed PMID: 4965319; PubMed Central PMCID: PMC2019877. 15: Hanlon TE, Schoenrich C, Freinek W, Turek I, Kurland AA. Perphenazine-benztropine mesylate treatment of newly admitted psychiatric patients. Psychopharmacologia. 1966;9(4):328-39. PubMed PMID: 4874349.